Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Income from Continuing Operations (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Income from Continuing Operations for 15 consecutive years, with 3709011.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 62.18% year-over-year to 3709011.0, compared with a TTM value of 14511974.0 through Sep 2025, down 20.08%, and an annual FY2024 reading of 11555194.0, up 24.08% over the prior year.
  • Income from Continuing Operations was 3709011.0 for Q3 2025 at BioRestorative Therapies, down from 3305287.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2286993.0 in Q3 2024 and bottomed at 15054656.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 4415630.63, with a median of 3709011.0 recorded in 2025.
  • The sharpest move saw Income from Continuing Operations tumbled 1738.2% in 2021, then soared 66.43% in 2022.
  • Year by year, Income from Continuing Operations stood at 4009267.0 in 2021, then decreased by 16.78% to 4681904.0 in 2022, then skyrocketed by 31.21% to 3220682.0 in 2023, then increased by 16.47% to 2690142.0 in 2024, then tumbled by 37.87% to 3709011.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BRTX at 3709011.0 in Q3 2025, 3305287.0 in Q2 2025, and 4807534.0 in Q1 2025.